State-of-the-art perspective: Advances in incretin-based therapy targeting progression of diabetes and cardiovascular-kidney-metabolic syndrome

Abstract

The incretin system is targeted in the treatment of type 2 diabetes mellitus (T2DM) and cardiovascular-kidney-metabolic (CKM) conditions. Increasingly, incretin hormones (i.e., gut peptides that enhance glucose-stimulated insulin secretion) reduce blood glucose levels, consequently alleviating CKM syndrome. Specifically, glucagon-like peptide 1 (GLP-1) demonstrated glucose-lowering effects, delayed gastric emptying, decreased glucagon secretion, and weight loss. An investigational medication, retatrutide, interacts as a tri-agonist with glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and the glucagon receptor. Contemporary data indicate that early intervention, targeting not only the GLP-1 receptor but also the GIP and glucagon receptors, are forthcoming therapeutics affecting T2DM in earlier phases and CKM outcomes, demonstrating the advances in tri-agonists versus only GLP-1. Notably, endogenous levels of gut incretin hormones shift as pre-diabetes progresses to diabetes or regresses to normoglycemia. The present perspective provides a review of incretin therapy and its prospects in hindering the progression of T2DM and CKM syndrome.

Keywords

Pre-diabetes / Type 2 diabetes / Cardiovascular-kidney-metabolic syndrome / Incretin mimetics / Obesity

Funding

None.

Conflict of interest

The authors declare no conflicts of interest.

References

[1] Centers for Disease Control. National Diabetes Statistics Report; 2024. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html#:-:text=prevalence%20of%20prediabetes%20among%20adults,in%202021%20 (table%204) [Last accessed on 2024 Jun 07].

[2] Parker ED, Lin J, Mahoney T, et al. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2024; 47(1):26-43. doi: 10.2337/dci23-0085

[3] Lu Y, Wang W, Liu J, Xie M, Liu Q, Li S. Vascular complications of diabetes: A narrative review. Medicine (Baltimore). 2023; 102(40):e35285. doi: 10.1097/MD.0000000000035285

[4] Ndumele CE, Rangaswami J, Chow SL, et al. American Heart Association. Cardiovascular-kidney-metabolic health: A presidential advisory from the American heart association. Circulation. 2023; 148:1606-1635. doi: 10.1161/CIR.0000000000001184

[5] American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1): S20-42. doi: 10.2337/dc24-S002

[6] Khan SS, Matsushita K, Sang Y, et al. Chronic kidney disease prognosis consortium and the American heart association cardiovascular-kidney-metabolic science advisory group. development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024; 149(6):430-449. doi: 10.1161/CIRCULATIONAHA.123.067626

[7] Schlesinger S, Neuenschwander M, Barbaresko J, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: Umbrella review of meta-analyses of prospective studies. Diabetologia. 2022; 65:275-285. doi: 10.1007/s00125-021-05592-3

[8] Biondi G, Marrano N, Borrelli A, et al. Adipose tissue secretion pattern influences β-Cell wellness in the transition from obesity to type 2 diabetes. Int J Mol Sci. 2022;23(10):5522. doi: 10.3390/ijms23105522

[9] Al-Omar HA, Czech M, Quang Nam T, et al. Cost saving analysis of prediabetes intervention modalities in comparison with inaction using Markov state transition model-A multiregional case study. J Diabetes. 2024; 16(5):e13553. doi: 10.1111/1753-0407.13553

[10] Chockalingam A, Natarajan P, Dorairajan S, Khan U. Early recognition of overweight hyperglycaemia may improve clinical outcomes in type 2 diabetes. touchREV Endocrinol. 2023; 19(1):33-37. doi: 10.17925/EE.2023.19.1.33

[11] Lizarzaburu-Robles JC, Herman WH, Garro-Mendiola A, Galdón Sanz-Pastor A, Lorenzo O. Prediabetes and cardiometabolic risk: The need for improved diagnostic strategies and treatment to prevent diabetes and cardiovascular disease. Biomedicines. 2024; 12(2):363. doi: 10.3390/biomedicines12020363

[12] Ko JH, Kim TN. Type 2 diabetes remission with significant weight loss: Definition and evidence-based interventions. J Obes Metab Syndr. 2022; 31(2):123-133. doi: 10.7570/jomes22001

[13] Tuomilehto J, Uusitupa M, Gregg EW, Lindström J. Type 2 diabetes prevention programs-from proof-of-concept trials to national intervention and beyond. J Clin Med. 2023;12:1876. doi: 10.3390/jcm12051876

[14] National Diabetes Prevention Program Website. Available from: https://coveragetoolkit.org/about-national-dpp/ndpp-overview [Last accessed on 2024 Jun 20].

[15] Braga T, Kraemer-Aguiar LG, Docherty NG, Le Roux CW. Treating prediabetes: Why and how should we do it? Minerva Med. 2019; 110(1):52-61. doi: 10.23736/S0026-4806.18.05897-4

[16] Morris AA, Masoudi FA, Abdullah AR, et al. 2024 ACC/AHA key data elements and definitions for social determinants of health in cardiology: A report of the American college of cardiology/American heart association joint committee on clinical data standards. Circ Cardiovasc Qual Outcomes. 2024; 17(10):e000133. doi: 10.1161/HCQ.0000000000000133

[17] American Heart Association. How to Get Healthy Sleep Fact Sheet. Available from: https://www.heart.org/en/-/media/healthy-living-files/le8-fact-sheets/le8_how_to_get_healthy_sleep.pdf?sc_lang=en [Last accessed on 2024 Dec 12].

[18] Nguyen S, Bellettiere J, Anuskiewicz B, et al. Prospective associations of accelerometer-measured machine-learned sedentary behavior with death among older women: The OPACH study. J Am Heart Assoc. 2024; 13(5):e031156. doi: 10.1161/JAHA.123.031156

[19] Samson SL, Vellanki P, Blonde L, et al. American association of clinical endocrinology consensus statement: Comprehensive type 2 diabetes management algorithm-2023 update. Endocr Pract. 2023; 29(5):305-340.

[20] Jakubowska A, Roux CW, Viljoen A. The road towards triple agonists: Glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor-an update. Endocrinol Metab (Seoul). 2024; 39(1):12-22. doi: 10.3803/EnM.2024.1942

[21] Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024; 391:299-310. doi: 10.1056/NEJMoa2401943

[22] Abdelmalek MF, Suzuki A, Sanchez W, et al. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis-study design and rationale of HM-TRIA-201 study. Contemp Clin Trials. 2023;130:107176. doi: 10.1016/j.cct.2023.107176

[23] Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66(10): 1780-1795. doi: 10.1007/s00125-023-05956-x

[24] Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102

[25] Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: Novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;66(10):1796-1808. doi: 10.1007/s00125-023-05929-0

[26] Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT 2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the flow trial. Nat Med. 2024; 30:2849-2856. doi: 10.1038/s41591-024-03133-0

[27] Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ. Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Am J Cardiol. 2024; 222:121-130. doi: 10.1016/j.amjcard.2024.04.041

[28] Teva Launches Generic Formulation of Liraglutide in US. Available from: https://www.pharmacytimes.com/view/teva-launches-generic-formulation-of-liraglutide-in-us [Last accessed on 2024 Jun 28].

[29] Scheen AJ. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Ann Endocrinol (Paris). 2023;84(2): 316-321. doi: 10.1016/j.ando.2022.12.423

[30] Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020; 5(17):e140532. doi: 10.1172/jci.insight.140532

[31] Zeitler P, Galindo RJ, Davies MJ, et al. Early-onset type 2 diabetes and tirzepatide treatment: A post hoc analysis from the SURPASS clinical trial program. Diabetes Care. 2024; 47(6):1056-1064. doi: 10.2337/dc23-2356

[32] Malhotra A, Bednarik J, Chakladar S, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial. Contemp Clin Trials. 2024; 141:107516. doi: 10.1016/j.cct.2024.107516

[33] ClinicalTrials.gov. Identifier: NCT04255433. A Study of Tirzepatide (LY3298176) Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT). Available from: https://clinicaltrials.gov/study/nct04255433 [Last accessed on 2024 Jun 10].

[34] Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. N Engl J Med. 2023; 389:514-526. doi: 10.1056/NEJMoa2301972

[35] Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401): 529-544. doi: 10.1016/S0140-6736(23)01053-X

[36] Jensen TL, Brønden A, Karstoft K, Sonne DP, Christensen MB. The body weight reducing effects of tirzepatide in people with and without type 2 diabetes: A review on efficacy and adverse effects. Patient Prefer Adherence. 2024;18: 373-382. doi: 10.2147/PPA.S419304

[37] Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. doi:10.1038/s41366-024-01473-y

[38] Locatelli JC, Costa JG, Haynes A, et al. Incretin-based weight loss pharmacotherapy: Can resistance exercise optimize changes in body composition? Diabetes Care. 2024:dci230100. doi: 10.2337/dci23-0100

[39] Conte C, Hall KD, Klein S. Is weight loss-induced muscle mass loss clinically relevant? JAMA. 2024; 332(1):9-10. doi: 10.1001/jama.2024.6586

[40] Pillai P, Modarressi T. GLP1RAs in Clinical Practice: Therapeutic Advances and Safety Perspectives; 2024. American College of Cardiology. Available from: https://www.acc.org/latest-in-cardiology/articles/2024/04/15/11/19/glp1ras-in-clinical-practice [Last accessed on 2024 Nov 02].

[41] Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024:e242296. doi: 10.1001/jamaophthalmol.2024.2296

[42] Małyszczak A, Przeździecka-Dołyk J, Szydełko-Paśko U, Misiuk-Hojło M. Novel antidiabetic drugs and the risk of diabetic retinopathy: A systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2024;13(6):1797. doi: 10.3390/jcm13061797

[43] Xu D, Nair A, Sigston C, et al. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations. Cardiovasc Ther. 2022:6820377. doi: 10.1155/2022/6820377

[44] Farr OM, Mantzoros CS. Treating prediabetes in the obese: Are GLP-1 analogues the answer? Lancet. 2017; 389: 1371-1372. doi: 10.1016/S0140-6736(17)30315-X

[45] Hoffmann C, Schwarz PE, Mantzoros CS, et al. Circulating levels of gastrointestinal hormones in prediabetes reversing to normoglycemia or progressing to diabetes in a year-A cross-sectional and prospective analysis. Diabetes Res Clin Pract. 2023; 199:110636. doi: 10.1016/j.diabres.2023.110636

[46] Le KDR, Le K, Foo F. The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: A scoping review. Pharmacy (Basel). 2024; 12(1):11. doi: 10.3390/pharmacy12010011